Evidence journal · July 2026

GLP-1 evidence & pricing journal

30 in-depth, source-backed briefings on compounded semaglutide and tirzepatide — the clinical trial data, the safety profile, the regulatory rules, and the cost math — each 1,000+ words with charts, tables, and physician review by Dr. A. Goher, MD.

How we rank. WeightLoss GLP-1 is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded semaglutide is not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.

Semaglutide (17 articles)

Tirzepatide (9 articles)

Comparisons & GLP-1 general (4 articles)